Novavax
NVAX
#5751
Rank
ยฃ0.84 B
Marketcap
ยฃ5.19
Share price
0.73%
Change (1 day)
-20.26%
Change (1 year)

Novavax (NVAX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : ยฃ1.00 Billion

According to Novavax's latest financial reports the company's total liabilities are ยฃ1.00 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novavax - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31ยฃ1.74 B-11.81%
2023-12-31ยฃ1.97 B-17.46%
2022-12-31ยฃ2.39 B10.22%
2021-12-31ยฃ2.16 B209.56%
2020-12-31ยฃ0.70 B156.01%
2019-12-31ยฃ0.27 B-7.56%
2018-12-31ยฃ0.29 B-0.99%
2017-12-31ยฃ0.29 B-7.7%
2016-12-31ยฃ0.32 B414.32%
2015-12-31ยฃ63 M111.48%
2014-12-31ยฃ29.79 M54.1%
2013-12-31ยฃ19.33 M41.37%
2012-12-31ยฃ13.67 M67.02%
2011-12-31ยฃ8.18 M-19.97%
2010-12-31ยฃ10.23 M5.77%
2009-12-31ยฃ9.67 M-54.47%
2008-12-31ยฃ21.24 M49.52%
2007-12-31ยฃ14.2 M-0.16%
2006-12-31ยฃ14.23 M-29.34%
2005-12-31ยฃ20.13 M-13.53%
2004-12-31ยฃ23.29 M-13.59%
2003-12-31ยฃ26.95 M-12.57%
2002-12-31ยฃ30.82 M12.82%
2001-12-31ยฃ27.32 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Agenus
AGEN
ยฃ0.38 B-61.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ1.63 B 62.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
ยฃ0.65 B-34.27%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
ยฃ0.62 B-37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
ยฃ51.40 B 5,023.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
ยฃ86.80 B 8,551.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
ยฃ46.94 B 4,578.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
ยฃ0.98 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
ยฃ46.00 B 4,485.23%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
ยฃ37.58 M-96.25%๐Ÿ‡บ๐Ÿ‡ธ USA